Accenture April 4, 2019

New Science expected to drive 54 percent of industry revenue through 2022, increase likelihood of regulatory approval of a new treatment, and raise the standard of patient care

NEW YORK: April 4, 2019 – The adoption of a unique combination of the best in science and health technology such as genomics, biomarkers and companion technologies are expected to be the biopharmaceutical industry’s new growth machine, according to new research from Accenture (NYSE: ACN).

This ‘New Science’ is filling an unmet need to advance the standard of care, and Accenture research found that companies that are leading in New Science are investing six to seven times as much money — US$250 million annually or more — in digital, data and genomics...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Market Research, Pharma, Precision Medicine, Provider, Technology, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article